Status:
COMPLETED
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
Lead Sponsor:
Novartis
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This is an 80-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people with ty...
Eligibility Criteria
Inclusion
- Only patients successfully completing study CLAF237A2327 are eligible
- Written informed consent
- Ability to comply with all study requirements
Exclusion
- Premature discontinuation from study CLAF237A2327
- Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
478 Patients enrolled
Trial Details
Trial ID
NCT00138619
Start Date
November 1 2004
End Date
April 1 2007
Last Update
May 7 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
2
Investigative Centers, Germany